ORMP
Price
$2.62
Change
+$0.11 (+4.38%)
Updated
Mar 11 closing price
Capitalization
106.02M
77 days until earnings call
PTGX
Price
$59.76
Change
+$3.81 (+6.81%)
Updated
Mar 11 closing price
Capitalization
3.67B
49 days until earnings call
Ad is loading...

ORMP vs PTGX

Header iconORMP vs PTGX Comparison
Open Charts ORMP vs PTGXBanner chart's image
Oramed Pharmaceuticals
Price$2.62
Change+$0.11 (+4.38%)
Volume$240.08K
Capitalization106.02M
Protagonist Therapeutics
Price$59.76
Change+$3.81 (+6.81%)
Volume$2.62M
Capitalization3.67B
ORMP vs PTGX Comparison Chart
Loading...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ORMP vs. PTGX commentary
Mar 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORMP is a StrongBuy and PTGX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Mar 12, 2025
Stock price -- (ORMP: $2.63 vs. PTGX: $59.76)
Brand notoriety: ORMP and PTGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ORMP: 74% vs. PTGX: 291%
Market capitalization -- ORMP: $106.02M vs. PTGX: $3.67B
ORMP [@Biotechnology] is valued at $106.02M. PTGX’s [@Biotechnology] market capitalization is $3.67B. The market cap for tickers in the [@Biotechnology] industry ranges from $355.07B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORMP’s FA Score shows that 1 FA rating(s) are green whilePTGX’s FA Score has 3 green FA rating(s).

  • ORMP’s FA Score: 1 green, 4 red.
  • PTGX’s FA Score: 3 green, 2 red.
According to our system of comparison, PTGX is a better buy in the long-term than ORMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORMP’s TA Score shows that 4 TA indicator(s) are bullish while PTGX’s TA Score has 5 bullish TA indicator(s).

  • ORMP’s TA Score: 4 bullish, 5 bearish.
  • PTGX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, PTGX is a better buy in the short-term than ORMP.

Price Growth

ORMP (@Biotechnology) experienced а +22.90% price change this week, while PTGX (@Biotechnology) price change was +54.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.43%. For the same industry, the average monthly price growth was -8.50%, and the average quarterly price growth was -7.70%.

Reported Earning Dates

ORMP is expected to report earnings on May 28, 2025.

PTGX is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (+0.43% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($3.67B) has a higher market cap than ORMP($106M). ORMP has higher P/E ratio than PTGX: ORMP (23.91) vs PTGX (14.13). PTGX YTD gains are higher at: 54.819 vs. ORMP (8.678). PTGX has higher annual earnings (EBITDA): 152M vs. ORMP (9.44M). PTGX has more cash in the bank: 469M vs. ORMP (142M). ORMP has less debt than PTGX: ORMP (429K) vs PTGX (10.9M). PTGX has higher revenues than ORMP: PTGX (324M) vs ORMP (0).
ORMPPTGXORMP / PTGX
Capitalization106M3.67B3%
EBITDA9.44M152M6%
Gain YTD8.67854.81916%
P/E Ratio23.9114.13169%
Revenue0324M-
Total Cash142M469M30%
Total Debt429K10.9M4%
FUNDAMENTALS RATINGS
ORMP vs PTGX: Fundamental Ratings
ORMP
PTGX
OUTLOOK RATING
1..100
8623
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
10025
SMR RATING
1..100
8121
PRICE GROWTH RATING
1..100
4536
P/E GROWTH RATING
1..100
3019
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PTGX's Valuation (68) in the Biotechnology industry is in the same range as ORMP (69) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew similarly to ORMP’s over the last 12 months.

PTGX's Profit vs Risk Rating (25) in the Biotechnology industry is significantly better than the same rating for ORMP (100) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew significantly faster than ORMP’s over the last 12 months.

PTGX's SMR Rating (21) in the Biotechnology industry is somewhat better than the same rating for ORMP (81) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew somewhat faster than ORMP’s over the last 12 months.

PTGX's Price Growth Rating (36) in the Biotechnology industry is in the same range as ORMP (45) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew similarly to ORMP’s over the last 12 months.

PTGX's P/E Growth Rating (19) in the Biotechnology industry is in the same range as ORMP (30) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew similarly to ORMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORMPPTGX
RSI
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
74%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 10 days ago
82%
Bearish Trend 16 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
View a ticker or compare two or three
Ad is loading...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
QUEXF0.59N/A
+0.54%
Q2 METALS CORP
BDRFY29.300.03
+0.11%
Beiersdorf AG
KNBWY14.060.01
+0.07%
Kirin Holdings Co., Ltd.
SFRGY3.69N/A
-0.14%
Salvatore Ferragamo S.P.A.
MPNGY43.65-0.20
-0.46%
MEITUAN

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BTAI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BTAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
+4.78%
BTAI - ORMP
44%
Loosely correlated
-17.17%
INO - ORMP
44%
Loosely correlated
-0.26%
MBIO - ORMP
44%
Loosely correlated
+1.33%
VERV - ORMP
44%
Loosely correlated
+3.53%
ZNTL - ORMP
43%
Loosely correlated
+2.51%
More

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with CKPT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then CKPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
+6.81%
CKPT - PTGX
48%
Loosely correlated
+0.25%
DNLI - PTGX
41%
Loosely correlated
+0.60%
ZYME - PTGX
39%
Loosely correlated
+5.23%
REPL - PTGX
38%
Loosely correlated
+2.60%
ORMP - PTGX
37%
Loosely correlated
+4.78%
More